Article may be outdated

This article is 3 days old. Some details may have changed since publication.

HCPLive·3 min read·hard

Fewer Severe ISM Symptoms After 4 Years of Avapritinib: Thanai Pongdee, MD

T
Thanai Pongdee, MD
Fewer Severe ISM Symptoms After 4 Years of Avapritinib: Thanai Pongdee, MD
✦AI Summary

A four-year study of the drug avapritinib shows significant symptom reduction in patients with indolent systemic mastocytosis. Most participants transitioned from severe to mild symptom categories with minimal safety concerns.

Why it matters

This long-term data provides evidence for the efficacy of targeted therapies in managing chronic, rare immune conditions.

✦Dive DeeperCreate a free account to unlock

Long-term avapritinib (Ayvakit) shifted most patients with indolent systemic mastocytosis (ISM) from severe to mild symptoms through 4 years in the PIONEER study, with no new safety concerns.1 Thanai Pongdee, MD, associate professor of medicine and research chair of the Division of Allergic Diseases at Mayo Clinic in Rochester, Minnesota, discussed the findings in an interview.

Pongdee presented the analysis at the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting, held November 12-16, 2026, in Phoenix, Arizona, building on earlier 4-year PIONEER quality-of-life data. In the randomized portion, avapritinib 25 mg once daily reduced ISM Symptom Assessment Form (ISM-SAF) total symptom score (TSS) more than placebo at week 24 (−15.6 vs −9.2 points; P = .003).2 As of September 17, 2025, 226 patients had initiated avapritinib 25 mg, with a median treatment duration of 46.5 months.1

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthscience
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in